|  | 
|  |  | 
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. | 
|   
 
    
    
    
May 9th, MGI received 2 broad based patents covering the compound MGI 114, the lead analog in the companies acylfulvene family of anti cancer compounds currently in Phase I human clinical trial.   The acylfulvenes potentially offer a unique theraputic advance in treating solid tumor types; lung, colon, breast, skin and others that are resistant to other forms of chemotherapy. They currently sell Salegen, which helps people who don't salivate after radiation therapy to the head and neck area. They make a profit with Salegen, and additional approval for other dry mouth applications are in the works. Dry mouth seems silly, but it really causes great health problems when it is chronic. They currently have no debt, but they aren't making a profit. Jim Adams is the contact at MGI (612) 935-7335. I talked to him today and he was very helpful. I'm not technically able to answer many questions, but I do have the annual report and will do my best. I'd appreciate any comments. Mark Oliver | ||||||||||||||
| 
 
 | 
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings | 
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI | 
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |